Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

2.

Options of flow cytometric three-colour DNA measurements to quantitate EGFR in subpopulations of human bladder cancer.

Brockhoff G, Endl E, Minuth W, Hofstädter F, Knüchel R.

Anal Cell Pathol. 1996 Jun;11(1):55-70.

PMID:
8844105
3.

Evaluation of flow-cytometric three-parameter analysis for EGFR quantification and DNA assessment in human bladder carcinomas.

Brockhoff G, Wieland W, Woelfl G, Hofstaedter F, Knuechel R.

Virchows Arch. 1998 Jan;432(1):77-84.

PMID:
9463591
4.

Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors.

Smith K, Fennelly JA, Neal DE, Hall RR, Harris AL.

Cancer Res. 1989 Nov 1;49(21):5810-5.

5.

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis.

Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J, Niehans GA.

Am J Clin Pathol. 1994 Feb;101(2):166-76.

PMID:
7906919
6.

Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma.

Chow NH, Tzai TS, Lin SN, Chan SH, Tang MJ.

Eur Urol. 1993;24(1):140-3.

PMID:
8365434
7.
8.
9.
10.

Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.

Guo CC, Fine SW, Epstein JI.

Am J Surg Pathol. 2006 Jul;30(7):883-91.

PMID:
16819332
11.
12.

Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7.

Amare Kadam PS, Varghese C, Bharde SH, Narasimhamoorthy NK, Desai S, Advani SH, Havaldar R, Kulkarni JN.

Cancer Genet Cytogenet. 2001 Mar;125(2):139-46.

PMID:
11369057
13.

Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma.

Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD, Chung LW.

Cancer Res. 1993 Nov 1;53(21):5300-7.

14.
15.
16.

Flow cytometric DNA analysis after immunoselection of bladder tumor cells with monoclonal antibody DU83.21.

Wright GL Jr, Alexander JP, Konchuba AM, Schellhammer PF, Schlossberg SM.

Cancer. 1990 Sep 15;66(6):1242-52.

PMID:
1698117
17.

Cellular F-actin levels as a marker for cellular transformation: correlation with bladder cancer risk.

Rao JY, Hemstreet GP 3rd, Hurst RE, Bonner RB, Min KW, Jones PL.

Cancer Res. 1991 Jun 1;51(11):2762-7.

18.

[Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer].

Lacombe L, Gauthier J, Lafleur L, Fradet Y.

Prog Urol. 1996 Dec;6(6):907-12. French.

PMID:
9235176
20.

Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.

Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, Abbou CC, Chopin DK.

Urol Oncol. 2004 Mar-Apr;22(2):93-101.

PMID:
15082004

Supplemental Content

Support Center